Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial).
Lijuan ZengJamie PerinAlden L GrossDavid ShadeKrista L LanctôtAlan J LernerJacobo E MintzerOlga Brawman-MintzerPrasad R PadalaChristopher H van DyckAnton P PorsteinssonSuzanne CraftAllan LeveyNathan HerrmannPaul B RosenbergPublished in: International journal of geriatric psychiatry (2024)
MPH use in AD patients for treating apathy is relatively safe, particularly notable given the many medical comorbidities in this population. There was a statistically significant but modest weight loss associated with MPH use, and clinicians are thus advised to monitor weight during MPH treatment.
Keyphrases
- weight loss
- end stage renal disease
- ejection fraction
- bariatric surgery
- newly diagnosed
- chronic kidney disease
- healthcare
- physical activity
- prognostic factors
- attention deficit hyperactivity disorder
- study protocol
- peritoneal dialysis
- palliative care
- clinical trial
- molecular docking
- randomized controlled trial
- cognitive decline
- roux en y gastric bypass
- type diabetes
- patient reported outcomes
- gastric bypass
- phase ii
- skeletal muscle
- insulin resistance
- mild cognitive impairment
- body weight